Search Results

PHAROS is a dedicated PET scanner intended to obtain Positron Emission Tomography (PET) images of parts of human body that fit in the patient aperture (brain, breast, arms and legs) to detect abnormal patterns of distribution of radioactivity after injection of a positron emitting radiopharmaceutical. This information can assist in diagnosis, therapeutic planning and therapeutic outcome assessment.

PHAROS is a specialized high-sensitivity and high-resolution PET system designed for imaging specific organs, such as the brain, breast, arms and legs.

Positron emission tomography (PET) captures images by detecting the distribution of internal radioactivity in human organs, utilizing radioactive pharmaceuticals. This technology reconstructs the body's internal biochemical and metabolic processes, producing high-resolution 3D visualizations. The method involves measuring a pair of simultaneous gamma rays, each with an energy of 511 keV, resulting from the annihilation of positrons. By labeling the positron emitter with a tracer and using a ring-shaped gamma ray detector, the spatial location of positron-emitting nuclides within the body is visualized.

PHAROS features four different scanning modes, each tailored for specific types of imaging:

1. Brain Scan Mode (Sitting Position):
   This mode is designed for brain imaging while the patient is seated.

2. Brain Scan Mode (Lying Position):
   This mode is designed for brain imaging while the patient lies down on a bed.

3. Breast Scan Mode:
   This mode is designed for breast imaging while the patient lies in a prone position.

4. Periphery Scan Mode:
   This mode is designed for imaging the periphery of the body, including the arms, hands, legs, and knees.

For both upper and lower extremity imaging, the height of detector head can be adjusted to ensure optimal patient comfort and accurate positioning. Aside from the physical height adjustment of the detector head, there is no difference in image acquisition method or image generation algorithm between upper and lower extremity scans.

Here's a summary of the acceptance criteria and study information for the PHAROS device, based on the provided FDA 510(k) clearance letter:

1. Table of Acceptance Criteria and Reported Device Performance

Ask a specific question about this device

The PHAROS Excimer Laser will be indicated for use for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma.

RA Medical Systems, Inc.'s PHAROS Excimer Laser is a medical laser that is a self-contained UV laser light source that emits a wavelength of 308 nm. The PHAROS Excimer Laser utilizes a XeCl gas mixture to generate an operator-selected dose and targetspecific UV light. The laser dose is activated by a footswitch with the therapeutic radiation emitting from a handheld device. The laser operation is key controlled and is contained within an interlocked housing.

This looks like a 510(k) premarket notification for a medical device. Based on the provided text, here's a breakdown of the requested information. It's important to note that this submission emphasizes substantial equivalence to predicate devices rather than a standalone clinical study with new acceptance criteria.

1. Table of Acceptance Criteria and Reported Device Performance

For this 510(k) submission, the "acceptance criteria" are based on demonstrating substantial equivalence to predicate devices, which implies that the new device (PHAROS EX-308 Excimer Laser) performs at least as well as and is as safe and effective as the existing devices for the stated indications. There are no specific quantitative performance metrics or acceptance criteria stated for the PHAROS EX-308 itself in this document, as the comparison is made against already cleared devices.

2. Sample Size Used for the Test Set and Data Provenance

The document does not describe a separate "test set" or a new clinical study with a specific sample size for the PHAROS EX-308 to prove its effectiveness. The submission relies on the established safety and effectiveness of its predicate devices. Therefore, there is no new data provenance (e.g., country of origin, retrospective/prospective) explicitly mentioned for a test set for this specific device. The "clinical performance testing" section explicitly states: "the indications requested have been previously cleared in predicate devices."

3. Number of Experts Used to Establish Ground Truth and Qualifications

Not applicable. Since no new clinical study data with human assessment as "ground truth" was conducted specifically for the PHAROS EX-308, information regarding experts for ground truth establishment is not provided. The "ground truth" for its effectiveness is implicitly derived from the prior clearances of the predicate devices based on their historical clinical trials (which are not detailed here).

4. Adjudication Method for the Test Set

Not applicable. As no new clinical study requiring ground truth establishment was conducted for the PHAROS EX-308, there is no mention of an adjudication method.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. The submission relies on substantial equivalence to existing predicate devices rather than a new comparative effectiveness study showing improvement with AI assistance (which is not relevant for this type of laser device).

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Yes, in a sense. The "Product Performance Testing" and "Clinical Performance Testing" sections confirm that testing was done on the PHAROS EX-308 laser itself to show it conforms to standards and performs equivalently to predicate devices. This can be seen as testing the "algorithm only" (the laser's physical and technical performance) in its standalone capacity, without necessarily a human-in-the-loop performance evaluation in a new clinical trial context.

7. The Type of Ground Truth Used

The "ground truth" used is essentially the prior clearances and established safety and effectiveness of the legally marketed predicate devices. The PHAROS EX-308 is deemed substantially equivalent because it shares the same intended use and similar technology, implying it will achieve similar clinical outcomes (safety and effectiveness) as those devices, for which the "ground truth" was established in their original clearance processes (likely through clinical trials and expert consensus at the time).

8. The Sample Size for the Training Set

Not applicable. This device is a laser system, not an AI/machine learning algorithm that requires a "training set" in the computational sense.

9. How the Ground Truth for the Training Set Was Established

Not applicable, as there is no "training set" for an AI/ML algorithm involved in this device.

Ask a specific question about this device

Acquire, store, transmit, and display medical images and patient reports of various types. Teleradiology image acquisition, distribution, archive and viewing.

The ISSA™ Imaging and PHAROS Communication Products is a lightly integrated package of software elements designed to provide:

• DICOM compliant telemedicine viewer interface
• 2D viewer of all stored medical images .
• . Telemedicine communication system
  In general terms, Issa PHAROS contains two software applications, Issa and Pharos. Both belong to the group of software produsts for medical image management and manipulations are designed to fit equaly to small medical units, such as imaging clinics or general practice clinics, and to large medical units such as hospitals or hospital departments. Image management and manipulation here means acquisition, archival, processing and transmission or distribution.

The provided text is a 510(k) Premarket Notification for the ISSA™ Imaging and PHAROS Communication Products. This document describes the device, its intended use, and its equivalence to a predicate device. However, it does not contain any information about acceptance criteria or a specific study proving the device meets those criteria, nor does it provide details about device performance metrics, sample sizes, ground truth establishment, or clinical study designs (MRMC, standalone).

The document states:

• "There are no applicable FDA mandated performance standards for this device."
• "The software described in the submission was developed, tested and validated in accordance with written Verification and Validation procedures."
• "No known hazardous procedures were detected during verification and testing that would be the consequence of software operation."

This indicates that while internal verification and validation were performed, no specific performance metrics or clinical study results are presented in this public summary to address the questions asked. The document is primarily a regulatory filing for substantial equivalence based on design and intended use, not a detailed technical performance report.

Therefore, I cannot populate the table or answer the specific questions regarding acceptance criteria, study details, sample sizes, expert qualifications, adjudication, or ground truth based on the provided text.

Ask a specific question about this device